Curevac's Motion To Transfer Patent Litigation Filed By Pfizer/BioNTech In Massachusetts Federal Court Has Been Granted, Moving It To Eastern District Of Virginia. The Transfer Is Expected To Significantly Accelerate Progress, With 2024 Likely Trial Date
Portfolio Pulse from Benzinga Newsdesk
Curevac's motion to transfer patent litigation filed by Pfizer/BioNTech to the Eastern District of Virginia has been granted, potentially accelerating progress with a likely trial date in 2024.
May 19, 2023 | 11:08 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
BioNTech's patent litigation with Curevac has been moved to the Eastern District of Virginia, potentially accelerating progress with a likely trial date in 2024.
The transfer of the patent litigation to the Eastern District of Virginia may accelerate the progress of the case, but the outcome remains uncertain. The trial date is still a few years away, so the short-term impact on BioNTech's stock price is likely to be neutral.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 100
NEUTRAL IMPACT
Curevac's patent litigation with Pfizer/BioNTech has been moved to the Eastern District of Virginia, potentially accelerating progress with a likely trial date in 2024.
The transfer of the patent litigation to the Eastern District of Virginia may accelerate the progress of the case, but the outcome remains uncertain. The trial date is still a few years away, so the short-term impact on Curevac's stock price is likely to be neutral.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 100
NEUTRAL IMPACT
Pfizer's patent litigation with Curevac has been moved to the Eastern District of Virginia, potentially accelerating progress with a likely trial date in 2024.
The transfer of the patent litigation to the Eastern District of Virginia may accelerate the progress of the case, but the outcome remains uncertain. The trial date is still a few years away, so the short-term impact on Pfizer's stock price is likely to be neutral.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 100